Hematology/Oncology

Top Story

Rapid growth of genetic genomic testing leads to ASCO policy statement update

August 31, 2015

ASCO updated its policy statement on genetic and genomic testing for cancer susceptibility.

The statement highlights the way new technologies have changed the assessment and identification of cancer susceptibility and provides guidance on the use of these technologies.

Regen developing new gene procedure for targeting liver cancer cells

August 31, 2015
Regen BioPharma, Inc. announced it is currently developing a gene delivery procedure that will enable RGBP-248, a gene silencing nucleic acid, to reach liver tumors and…
Gregory Masters In the Journals

ASCO updates guideline on treatment of advanced NSCLC

August 31, 2015
ASCO has updated its clinical practice guideline on systemic therapy for stage IV non–small cell lung cancer.The evidence-based recommendations provide guidance on…

Patients with RA may be at greater risk for developing lung cancer, lymphoma

August 31, 2015
Patients with rheumatoid arthritis may have a higher risk for developing lung cancer or lymphoma compared with the general population but may be at lower risk for…
FDA News

FDA grants priority review to MCNA for nonmuscle-invasive bladder cancer

August 31, 2015
The FDA granted priority review to MCNA for patients with high-risk nonmuscle-invasive bladder cancer, according to a press release from the drug’s…
More News Headlines »
CME
Hematology Oncology Case Consults

The Patient with Chronic Lymphocytic Leukemia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with chronic lymphocytic leukemia.
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
CME
Immunotherapy Updates 2015: FOCUS on NSCLC

Immunotherapy Updates 2015: FOCUS on NSCLC

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for…
More »
morganatic-roan